|
Match
|
Document |
Document Title |
|
|
US20090299036 |
AGENT FOR PREVENTING ARTERIOSCLEROSIS, AGENT FOR SUPPRESSING VASCULAR INTIMAL THICKENING AND AGENT FOR IMPROVING VASCULAR ENDOTHELIAL FUNCTION
There is provided an agent having at least one of an improving effect on vascular endothelial functions and an inhibitory effect on vascular intimal thickening, as well as a prophylactic of...
|
|
|
US20090292129 |
PROCESS FOR RESOLVING RACEMIC MIXTURES AND A DIASTEREOISOMERIC COMPLEX OF A RESOLVING AGENT AND AN ENANTIOMER OF INTEREST
A process for resolving a compound in racemic form comprising the following steps is described: a) reacting a compound in racemic form with a resolving agent, b) forming a diastereoisomeric complex...
|
|
|
US20090281162 |
Crystalline forms of atorvastatin
The present invention is directed to new crystalline forms of Atorvastatin calcium (2:1), referred to hereinafter as polymorphic Forms X, A, B1, B2, C, D and E. Furthermore, the present invention...
|
|
|
US20090275752 |
Novel Process for Statins and its Pharmaceutically Acceptable Salts Thereof
Novel process for statins and its pharmaceutically acceptable salts thereof represented by general formula (I).
|
|
|
US20090258912 |
N-(1-Alkyl-2-Phenylethyl)-Carboxamide Derivatives and Use Thereof as Fungicides
A compound of general formula (I):
A process for preparing this compound. A fungicidal composition comprising a compound of general formula (I). A method for treating plants by applying a...
|
|
|
US20090253671 |
TRICYCLIC DERIVATIVES OF AZETIDINE AND PYRROLE WITH ANTIBACTERIAL ACTIVITY
Compounds of formula (I) and their pharmaceutically acceptable salts are described. Processes for their preparation, pharmaceutical compositions containing them, their use as medicaments and their...
|
|
|
US20090240064 |
CRYSTALLINE FORM OF ATORVASTATIN HEMI-CALCIUM
The present invention relates to a new crystalline form of Atorvastatin hemi-calcium and also relates to a process for preparation of the same by treating Atorvastatin hemi-calcium amorphous form...
|
|
|
US20090239866 |
PEPTIDE DEFORMYLASE INHIBITORS
Novel PDF inhibitors and novel methods for their use are provided.
|
|
|
US20090233968 |
INHIBITORS OF THE ALPHA2BETA1/GPIa-IIA INTEGRIN
Novel compounds inhibiting the integrin α2β1/GPIa-IIa receptor are disclosed. Also disclosed are pharmaceutical compositions containing the compounds, as well as methods of their therapeutic use....
|
|
|
US20090233274 |
DRUG DEVELOPMENT TARGET PROTEIN AND TARGET GENE, AND METHOD OF SCREENING
The present invention provides novel target proteins and target genes for drug discovery, and the means that enable the development of novel drugs using the same. More particularly, the present...
|
|
|
US20090226510 |
PHARMACEUTICAL COMPOSITIONS OF ATORVASTATIN
A unit dosage form comprising atorvastatin or a pharmaceutically acceptable salt thereof, prepared without a granulation step, wherein the measured atorvastatin potency of said dosage form shows a...
|
|
|
US20090221667 |
Process for Annealing Amorphous Atorvastatin
Processes for annealing amorphous atorvastatin is described. Pharmaceutical compositions and formulations containing annealed amorphous atorvastatin are also described.
|
|
|
US20090216029 |
PROCESS FOR THE PRODUCTION OF ATORVASTATIN CALCIUM IN AMORPHOUS FORM
A process for the production of amorphous atorvastatin calcium and stabilized, amorphous atorvastatin calcium is provided.
|
|
|
US20090215855 |
New Crystalline Atorvastatin Hemicalcium Salt Polymorph Form
The present invention relates to a new crystalline polymorph B-52 form of atorvastatin hemicalcium salt [A[(3R,5R)-7-[3-phenyl-4-[(phenyl...
|
|
|
US20090209612 |
PROCESS FOR THE PREPARATION OF ATORVASTATIN
The invention relates to processes for the preparation of atorvastatin. Atorvastatin is known by the chemical name...
|
|
|
US20090196932 |
PHARMACEUTICAL COMPOSITIONS OF ATORVASTATIN
A dry-granulated pharmaceutical composition comprising atorvastatin or a pharmaceutically acceptable salt thereof, as well as a dry-granulated pharmaceutical composition comprising atorvastatin or...
|
|
|
US20090192172 |
2-Alkyl-Cycloalk(en)yl-Carboxamides
Novel 2-alkylcycloalk(en)ylcarboxamides of the formula (I)
in which
X, s, R 1 , L, R 2 and A are as defined in the description,
a plurality of processes for preparing these compounds...
|
|
|
US20090182030 |
PROCESS FOR THE PREPARATION OF AMORPHOUS CALCIUM SALT OF ATORVASTATIN
A process for the preparation of amorphous atorvastatin calcium. The process includes providing a reaction mixture having a pH between 6.5 and 8.0 containing a sodium salt of atorvastatin and...
|
|
|
US20090171099 |
PROCESS FOR THE PRODUCTION OF AMORPHOUS ATORVASTATIN CALCIUM
A novel process of the preparation of amorphous atorvastatin calcium starting from a compound of Formula (II).
|
|
|
US20090124817 |
Process for Preparing Amorphous Atorvastatin Calcium Nanoparticles
The present invention relates to a method of preparing amorphous atorvastatin calcium nanoparticles using a supercritical fluid process. Specifically, the method comprising the steps of: a)...
|
|
|
US20090118520 |
PROCESS FOR PREPARATION OF (3R, 5R)-7-[2-(4-FLUOROPHENYL)-5-ISOPROPYL-3-PHENYL-4-[(4-HYDROXY METHYL PHENYL AMINO) CARBONYL]-PYRROL-1-YL]-3,5-DIHYDROXY-HEPTANOIC ACID HEMI CALCIUM SALT
The present invention relates to processes for the preparation of (3R, 5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[(4-hydroxy
methyl phenyl...
|
|
|
US20090111731 |
NOVEL TOPICAL APPLICATION AGENTS AGAINST MIMIC AND AGE-RELATED WRINKLES
The compounds of formula (I)
wherein
X represents a bond or NH—CH(C═O)—(CH 2 ) 3+n —NH—R 5 , n represents 0, 1 or 2, R 1 , R 4 and R 5 —independently from each other—represent...
|
|
|
US20090099371 |
PROCESS FOR THE PREPARATION OF AMORPHOUS ATORVASTATIN CALCIUM SALT
Disclosed is a novel process for preparing pure amorphous form of Atorvastatin employing a suitable solvent system selected from water, water-miscible solvents or water-immiscible solvents or a...
|
|
|
US20090099242 |
Heterocyclic inhibitors of necroptosis
The invention features a series of heterocyclic derivatives that inhibit tumor necrosis factor alpha (TNF-α) induced necroptosis. The heterocyclic compounds of the invention are described by...
|
|
|
US20090093472 |
ORTHO PYRROLIDINE, BENZYL-SUBSTITUTED HETEROCYCLE CCR1 ANTAGONISTS FOR AUTOIMMUNE DISEASES & INFLAMMATION
Compounds of the formula
are disclosed. The compounds are CCR1 antagonists which are useful for the treatment and prevention of inflammatory and autoimmune diseases. Other embodiments are also...
|
|
|
US20090082421 |
Crystalline Form B4 of Atorvastatin Magnesium and a Process Thereof
Crystalline polymorphic form B4 of Atorvastatin magnesium of FIG. 1 and processes for its preparation.
|
|
|
US20090081801 |
Process for synthesis of pyrrole derivative, an intermediate for atorvastatin
The present invention also relates to a novel impurity,...
|
|
|
US20090054496 |
MICROBIOCIDES
The invention relates to a fungicidally active compound of the general Formula (I): where Het is a 5- or 6-membered heterocyclic ring containing one to three heteroatoms, each independently...
|
|
|
US20090048453 |
Salt forms of [R-(R*,R*)]-2-(4-fluorophenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid
Novel salt forms of [R—(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methyl
ethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-hepta
noic acid characterized by their X-ray powder...
|
|
|
US20090041721 |
ARYLALKOXYL HEPATITIS C VIRUS PROTEASE INHIBITORS
The present invention discloses compounds of Formula I or II, or pharmaceutically acceptable salts, esters, or prodrugs thereof:
which inhibit serine protease activity, particularly the activity...
|
|
|
US20090023935 |
Process for Producing 3,4-Disubstituted Pyrrolidine Derivative and Production Intermediate Thereof
An industrially advantageous process for the production of (3R,4S)-3-cyclopropylaminomethyl-4-fluoropyrrolidine or an enantiomer thereof that is useful as an intermediate for the production of...
|
|
|
US20090018182 |
Crystalline forms of atorvastatin
Novel forms of atorvastatin hemi-calcium have been prepared and characterized. These novel forms are particularly useful in pharmaceutical compositions.
|
|
|
US20090012312 |
Process for Preparing Pyrrole Derivatives and Intermediates
The present invention relates to a process for preparing pyrrole derivatives of a class that is effective at inhibiting the biosynthesis of cholesterol in humans, and more particularly to improved...
|
|
|
US20080312457 |
Process
The present invention relates to a new process for the resolution of mandelic acid derivatives from racemic mandelic acid derivative mixtures by salt formation with chiral base cyclic amides; to...
|
|
|
US20080306282 |
Novel Forms of [R-(R*,R*)]-2-(4-Fluorophenyl)-Beta,Delta-Dihydroxy-5-(1-Methylethyl)-3-Phenyl-4-[(Phenylamino)Carbonyl]-1H-Pyrrole-1-HeptanoicAcid Calcium Salt (2:1)
Novel forms of [R—(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methyl
ethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-hepta
noic acid hemi calcium salt designated Form XX, Form XXI,...
|
|
|
US20080287690 |
Process For (3R, 5R)-7-[2-(4-Fluorophenyl)-5-Isopropyl-3-Phenyl-4- [(4-Hydroxy Methyl Phenyl Amino) Carbonyl]-Pyrrol-1-Yl]-3,5-Dihydroxy-Heptanoic Acid Hemi Calcium Salt
The present invention relates to processes for the manufacture of (3R, 5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[(4-hydroxy
methyl phenyl...
|
|
|
US20080287449 |
AZA-TRIPEPTIDE HEPATITIS C SERINE PROTEASE INHIBITORS
The present invention relates to compounds of Formula I, or a pharmaceutically acceptable salt, ester, or prodrug, thereof:
which inhibit serine protease activity, particularly the activity of...
|
|
|
US20080280971 |
DEUTERIUM-ENRICHED ATORVASTATIN
The present application describes deuterium-enriched atorvastatin, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.
|
|
|
US20080269315 |
Crystalline form
The present invention is directed to the novel polymorphic Form F of Atorvastatin calcium, processes for the preparation thereof and pharmaceutical compositions comprising this crystalline form.
|
|
|
US20080262230 |
Benzyloxypropylamine Derivative
Disclosed is a novel benzyloxypropylamine derivative having an excellent tachykinin receptor antagonistic effect. This compound shows a good transfer into the blood and a long blood half-life in...
|
|
|
US20080262074 |
Salt Forms of [R-(R*,R*)]-2-(4-Fluorophenyl)-Beta,Delta-Dihydroxy-5-(1-Methylethyl)-3-(Phenyl-4-[(Phenylamino)Carbonyl]-1H-Pyrrole-1-Heptanoic Acid
Novel salt forms of [R—(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methyl
ethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-hepta
noic acid or solvates or hydrates thereof, as well as...
|
|
|
US20080262073 |
Pyrrolic Derivatives with Histone Deacetylase Inhibitory Activity
The invention describes new compounds derived from formula I pyrroles, methods for obtaining them and their application as drugs in pharmaceutical compositions for the treatment of cancer due to...
|
|
|
US20080249157 |
Novel Inhibitors of the Lfa-1/Icam-1 Interaction and Uses Thereof
The invention relates to the treatment of disorders or diseases mediated by LFA-1/ICAM-1 molecular interaction. This is based on the use of novel chemical compounds capable of inhibiting said...
|
|
|
US20080248539 |
COMPOSITIONS AND METHODS FOR PRODUCING STEREOISOMERICALLY PURE STATINS AND SYNTHETIC INTERMEDIATES THEREFOR
The present disclosure provides ketoreductase enzymes having improved properties as compared to a naturally occurring wild-type ketoreductase enzyme. Also provided are polynucleotides encoding the...
|
|
|
US20080242861 |
Synthesis of amino-protected cyclohexane-1,4-diyldimethanamine and its derivatives
This invention relates to methods of preparing the compounds of formula (V):
Each variable in this formula is defined in the specification.
|
|
|
US20080234270 |
Pyrrole Derivatives As Pharmaceutical Agents
Compounds, compositions and methods for modulating the activity of receptors are provided. In particular compounds and compositions are provided for modulating the activity of receptors and for the...
|
|
|
US20080221181 |
COMPOUNDS FOR TREATING TUMORS
The invention provides compounds of formula (I):
wherein E, A, B′, R 6 , R 7 , R 8 , and R 9 are defined in the specification which compounds exhibit anticancer activity and are useful for...
|
|
|
US20080214650 |
Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel process for preparing other forms
The present invention provides novel forms of atorvastatin designated Forms VI, VIII, IX, X, XI and XII and novel processes for their preparation as well as processes for preparing atorvastatin...
|
|
|
US20080214532 |
Carboxanilides as Microbiocides
Compounds of the formula (I) in which the substituents are as defined in claim 1 are suitable for use as microbiocides.
|
|
|
US20080200533 |
Drug or Pharmaceutical Compounds and a Preparation Thereof
The administration of pharmaceuticals of drugs which are having less solubility, lower bioavailability, lower bioabsorbability, less rate of absorption has become a big challenge in day to day...
|